Ceftibuten一个新的口服三代头孢菌素

CEFTIBUTEN-A NEW ORAL THIRD GENEVATION CEPHALOSPORIN

Ceftibuten是一个口服三代头孢菌素，它对革兰氏阴性杆菌具有较强的抗菌活性，其MIC50为0．25mg／L，MIC(90)为8mg／L。但对链球菌的抗菌活性弱，其MIC(50)。为2mg／L，MIC(90)为4mg／L。Ceftibuten对TEM型的超广谱β-内酰胺酶稳定。用Ceftibuten治疗下呼吸道和泌尿道感染的临床试验结果表明：其临床有效率分别为84．3－93％，87％。细菌清除率分别为79—90％，87％。并且在治疗过程中无明显不良反应。

Ceftibuten, a new oral third - generation cephalosporin. had high activity against gram - negative enterobacter spp. The MIC(50) and MIC(90) were 0.25 mg/L and 8 mg/L, respectively.But it had less activity against Streptococcus spp. The MIC(50)and MIC(90) were 2 mg/ L and 4 mg/ L,respectively. It had no activity against P. aeruginosa and Enterococcus spp. Ceftibuten was stable to TEM extended broad spectrum β - lactamases. The clinical trails showed the effective rates for ceftibuten in lower respiratory tract infections and in urinary tract infections were 84. 5% - 93% and 87%, respectively, the bacteriological eradiction rates for ceftibuten were 79 - 90% and 7O%, respectively. Moreover, the adverse reaction was mild.